合并HBV非小细胞肺癌化疗同时使用抗病毒治疗的临床应用  

The Clinical Applications of Combined HBV Approach to Chemotherapy for Non-small Cell Lung Cancer while Adoption of Antivirus Therapy

作　　者：段林灿[1] 李高峰[1] 张勇[1] 叶联华[1] 

机构地区：[1]昆明医学院第三附属医院(云南省肿瘤医院)胸外科,云南省肿瘤研究所肺癌研究中心,昆明650118

出　　处：《中国肺癌杂志》2009年第8期893-895,共3页Chinese Journal of Lung Cancer

摘　　要：背景与目的肺癌已经成为当今世界对人类健康与生命危害最大的恶性肿瘤,化疗延迟或中止是影响其预后的原因之一。本研究旨在探讨合并HBV非小细胞肺癌患者化疗同时使用抗病毒治疗的必要性。方法选择合并HBV的ⅢA非小细胞肺癌患者60例,随机分为实验组和对照组,实验组采用NP方案化疗的同时加拉米夫定(Np+Lam组),对照组仅用NP方案化疗(Np组),比较Np+Lam组和Np组肝功能损伤、免疫功能损伤和HBV再激活有无统计学差异。结果化疗后Np+Lam组和Np组血清ALT水平都升高,且Np组血清ALT水平明显高于Np+Lam组(P<0.05);化疗结束后Np+Lam组和Np组CD3+、CD4+和CD4+/CD8+百分比下降,CD8+百分比上升,而且两组间差异具有统计学意义(P<0.05);Np+Lam组和Np组发生HBV再激活和发生化疗延迟或中断情况间有明显统计学差异(P<0.05)。结论合并HBV非小细胞肺癌患者化疗同时有必要使用抗病毒治疗。Background and objective Lung cancer has become the most serious malignant tumor threating the human beings＇ health and life, and chemotherapy postponing or suspending contributes to one of the prognostic causes. In this research, we try to explore the importance of combined HBV approach to chemotherapy for non-small cell lung cancer while adoption of antivirus therapy. Methods Select 60 cases of patients suffering from combined HBV IliA non-small cell lung cancer, who were divided into two groups, the experimental group and control group. For the experimental group, a NP-approach chemotherapy was adopted along with addition of Lamivudine （NP＋Lam group）, while for the control group, only NP-approach was applied （NP group）, in order to compare whether there would be any statistical difference between the two groups in terms of damage to the functions of liver and immune system as well as reactivation of HBV. Results The blood serum of the patients from both of the two groups rises, with the NP group being prominently higher than the NP＋Lam group on an average （P〈0.05）. Upon completion of the chemotherapy, the percentage of CD3^＋/CD4^＋ and CD4^＋/CD8^＋ decreases. As the percentage of CD8^＋ increases, the differences in these items turn out to be marked （P〈0.05）. The reactivation of HBV and postponing or suspending of the chemotherapy are also find prominently different （P〈0.05）. Conclusion It is necessary to use antiviral therapy while the patents with combined non-small cell lung cancer receive therapy.

关 键 词：肺肿瘤 乙型肝炎 抗病毒 HBV再激活 

分 类 号：R734.2[医药卫生—肿瘤]